US Patent No: 7,682,634

Number of patents in Portfolio can not be more than 2000

Pharmaceutical compositions

Stats

ALSO PUBLISHED AS: 20090162451
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ALPHARMA PHARMACEUTICALS, LLCBRIDGEWATER, NJ7

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Boehm, Garth - 32 165
Liang, Alfred - 30 85
Matthews, Frank Alpharetta, GA 22 57
Tang, Lijuan Flemington, NJ 13 26

Cited Art

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (51)
4,828,836 Controlled release pharmaceutical composition 127 1987
4,834,985 Controlled release pharmaceutical composition 160 1987
4,990,341 Controlled release hydromorphone composition 83 1989
5,266,331 Controlled release oxycodone compositions 91 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 123 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 124 1992
5,549,912 Controlled release oxycodone compositions 79 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 108 1993
5,580,578 Controlled release formulations coated with aqueous dispersions of acrylic polymers 96 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 81 1993
5,411,745 Powder-layered morphine sulfate formulations 60 1994
5,965,161 Extruded multi-particulates 59 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 233 1995
5,508,042 Controlled release oxycodone compositions 79 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 87 1995
5,958,459 Opioid formulations having extended controlled released 50 1995
5,656,295 Controlled release oxycodone compositions 66 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 55 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 88 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 62 1997
5,958,452 Extruded orally administrable opioid formulations 75 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 45 1997
6,077,533 Powder-layered oral dosage forms 36 1998
6,228,863 Method of preventing abuse of opioid dosage forms 69 1998
6,277,384 Opioid agonist/antagonist combinations 48 1998
6,103,261 Opioid formulations having extended controlled release 50 1999
6,335,033 Melt-extrusion multiparticulates 39 1999
6,261,599 Melt-extruded orally administrable opioid formulations 62 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 62 1999
6,316,031 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 14 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 59 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 45 2001
6,475,494 Opioid agonist/antagonist combinations 36 2001
2002/0058,673 Opioid agonist/opioid antagonist/acetaminophen combinations 21 2001
6,905,709 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 10 2001
7,125,561 Compartmentalized dosage form 6 2002
7,144,587 Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent 23 2002
7,332,182 Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant 20 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 23 2002
2003/0157,168 Sequestered antagonist formulations 31 2002
6,696,066 Opioid agonist/antagonist combinations 35 2002
7,070,806 Controlled release formulations coated with aqueous dispersions of acrylic polymers 9 2002
2004/0186,121 Tamper-resistant oral opioid agonist formulations 14 2003
7,172,767 Opioid agonist / antagonist combinations 19 2003
2004/0241,218 Abuse resistant opioid containing transdermal systems 12 2003
6,865,444 Container and method for dispensing transdermal dosage forms 25 2003
7,384,653 Oral dosage form comprising a therapeutic agent and an adverse-effect agent 6 2004
2006/0198,881 Tamper resistant transdermal dosage form 3 2005
2006/0182,801 Sequestered antagonist formulations 17 2006
2007/0014,732 Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent 18 2006
7,419,686 Opioid agonist/antagonist combinations 9 2006
 
EURO-CELTIQUE S.A. (35)
4,366,310 Controlled release compositions 27 1980
4,940,587 Oral pharmaceutical composition through mucosa 71 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 97 1986
4,834,965 Controlled release pharmaceutical composition 58 1987
4,867,985 Spheroids 63 1988
5,071,646 Pharmaceutical ion exchange resin composition 73 1989
5,091,189 Controlled release dosage forms having a defined water content 24 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 54 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 62 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 92 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 92 1993
5,622,722 Spheroid formulation 24 1994
5,508,043 Controlled release matrix for pharmaceuticals 31 1995
5,670,172 Pharmaceutical spheroid formulation 44 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 53 1995
5,811,126 Controlled release matrix for pharmaceuticals 48 1995
5,763,452 Pharmaceutical compositions and usages 23 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 58 1996
5,891,471 Pharmaceutical multiparticulates 49 1996
5,601,845 Pharmaceutical spheroid formulation 55 1996
5,843,480 Controlled release diamorphine formulation 41 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 54 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 24 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 76 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 38 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 57 1997
6,077,532 Pharmaceutical ion exchange resin composition 30 1998
6,306,438 Stabilized sustained release tramadol formulations 37 1998
6,399,096 Pharmaceutical formulation 29 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 27 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 40 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 34 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 33 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 37 2001
6,627,635 Method of preventing abuse of opioid dosage forms 41 2001
 
ALZA CORPORATION (13)
4,327,725 Osmotic device with hydrogel driving member 533 1980
4,519,801 Osmotic device with wall comprising cellulose ether and permeability enhancer 60 1982
4,576,604 Osmotic system with instant drug availability 83 1983
4,588,580 Transdermal administration of fentanyl and device therefor 160 1984
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 102 1984
4,612,008 Osmotic device with dual thermodynamic activity 225 1984
4,655,766 Fluid imbibing pump with self-regulating skin patch 54 1986
5,236,714 Abusable substance dosage form having reduced abuse potential 56 1988
5,021,053 Oral osmotic device with hydrogel driving member 40 1989
5,198,229 Self-retaining gastrointestinal delivery device 27 1991
5,326,571 Dosage forms comprising polymers comprising different molecular weights 23 1992
5,460,826 Morphine therapy 59 1994
5,866,164 Composition and dosage form comprising opioid antagonist 68 1997
 
ALPHARMA PHARMACEUTICALS, LLC (8)
5,202,128 Sustained release pharmaceutical composition 111 1990
5,330,766 Sustained release pharmaceutical composition 74 1993
5,378,474 Sustained release pharmaceutical composition 79 1993
2004/0131,552 Sequestering subunit and related compositions and methods 32 2003
2008/0233,197 Pharmaceutical compositions 10 2007
2008/0233,156 Pharmaceutical compositions 10 2007
2009/0131,466 Pharmaceutical Compositions 10 2008
2009/0162,450 PHARMACEUTICAL COMPOSITION 2 2009
 
ENDO PHARMACEUTICALS INC. (6)
2003/0004,177 Abuse-resistant opioid dosage form 52 2002
2003/0065,002 Abuse-resistant controlled-release opioid dosage form 12 2002
2003/0157,167 Oxymorphone controlled release formulations 7 2002
2008/0318,993 Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment 5 2007
2008/0318,994 Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment 5 2007
2008/0069,881 Abuse-resistant controlled-release opioid dosage form 10 2007
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 41 1981
4,730,048 Gut-selective opiates 50 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 67 1992
5,457,208 Kappa opioid receptor antagonists 51 1993
5,578,725 Delta opioid receptor antagonists 35 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 29 1997
 
MERCK FROSST CANADA & CO. (5)
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 59 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 70 1994
5,536,752 Phenyl heterocycles as COX-2 inhibitors 54 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 61 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 48 1995
 
MERCK FROSST CANADA LTD. (5)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 47 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 58 1993
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 77 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 65 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 50 1995
 
ACTAVIS ELIZABETH LLC (4)
5,834,024 Controlled absorption diltiazem pharmaceutical formulation 27 1997
6,033,687 Controlled absorption diltiazem pharmaceutical formulation 19 1999
6,214,385 Controlled absorption diltiazem pharmaceutical formulation 9 1999
7,067,151 Controlled absorption diltiazem pharmaceutical formulation 3 2000
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (4)
5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 62 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 29 1995
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 47 1996
6,765,010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 19 2002
 
LAB INTERNATIONAL SRL (4)
2008/0069,871 HYDROPHOBIC ABUSE DETERRENT DELIVERY SYSTEM 8 2007
2008/0075,768 HYDROPHOBIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS 4 2007
2008/0075,770 HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM 4 2007
2008/0075,771 HYDROPHILIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS 9 2007
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 52 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 47 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 49 1990
5,972,954 Use of methylnaltrexone and related compounds 57 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 60 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 91 1993
5,502,058 Method for the treatment of pain 71 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 85 1994
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (3)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 49 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 44 1993
5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 49 1995
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 52 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 39 1989
5,086,058 Method for treating alcoholism with nalmefene 50 1990
 
KINAFORM TECHNOLOGY, INC. (3)
5,376,384 Delayed, sustained-release pharmaceutical preparation 35 1992
5,478,573 Delayed, sustained-release propranolol pharmaceutical preparation 25 1994
5,529,790 Delayed, sustained-release diltiazem pharmaceutical preparation 21 1994
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 50 1994
6,326,027 Controlled release formulation 37 1995
6,254,887 Controlled release tramadol 35 1996
 
SCHAAP; ROBERT J. (3)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 43 1992
5,935,975 Agonist-antagonist combination to reduce the use of nicotine and other drugs 16 1993
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 87 1994
 
THE ROCKEFELLER UNIVERSITY (3)
4,987,136 Method for controlling gastrointestinal dysmotility 80 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 57 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 39 1987
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 34 1985
4,957,681 Preparation of pharmaceutical mixtures 65 1989
 
DURECT CORPORATION (2)
5,312,389 Osmotically driven syringe with programmable agent delivery 49 1992
2006/0257,460 Multilayer drug delivery system with barrier against antagonist exposure 3 2006
 
DYNAGEN, INC. (2)
5,403,595 Controlled, sustained release delivery system for smoking cessation 18 1993
5,486,362 Controlled, sustained release delivery system for treating drug dependency 66 1993
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 40 1982
5,593,994 Prostaglandin synthase inhibitors 43 1994
 
ELI LILLY AND COMPANY (2)
4,293,539 Controlled release formulations and method of treatment 74 1979
5,998,434 Composition for treating pain 28 1998
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 77 1987
4,844,910 Spheroids 33 1987
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 44 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 48 1987
 
OMEROS CORPORATION (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 81 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 65 1996
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 95 1986
4,970,075 Controlled release bases for pharmaceuticals 74 1989
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 62 1984
4,661,492 Analgesic compositions 47 1985
 
ROHM GMBH (2)
2006/0269,605 Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances 17 2004
2007/0042,045 Multilayer dosage form comprising a matrix that influences release of a modulatory substance 13 2004
 
SCULLY SCOTT MURPHY & PRESSER, PC (2)
5,266,574 Growth regulation and related applications of opioid antagonists 12 1991
5,426,112 Growth regulation and related applications of opioid antagonists 49 1993
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 29 1991
 
AMINOTEK SCIENCES, INC. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 39 1992
 
APTALIS PHARMATECH, INC. (1)
2004/0110,781 Pharmaceutical compositions containing indistinguishable drug components 7 2002
 
ARADIGM CORPORATION (1)
5,507,277 Lockout device for controlled release of drug from patient-activateddispenser 76 1994
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 38 1989
 
BENZON PHARMA, A DANISH LIMITED COMPANY (1)
4,606,909 Pharmaceutical multiple-units formulation 77 1984
 
BIESER, ALBERT H. (1)
5,189,064 Treatment of cocaine addiction 40 1990
 
BIOVITRUM AB (1)
5,565,455 Method for treating substance abuse disorders 7 1994
 
BOEHRINGER INGELHEIM ROXANE, INC. (1)
2005/0163,856 Abuse-resistant sustained-release opioid formulation 11 2005
 
BRISTOL-MYERS COMPANY (1)
4,457,933 Prevention of analgesic abuse 62 1981
 
BRISTOL-MYERS SQUIBB PHARMA COMPANY (1)
4,626,539 Trandermal delivery of opioids 65 1985
 
BRUKER HTS GMBH (1)
2006/0182,891 Method and apparatus for producing biaxially oriented thin films 3 2006
 
CITA BIOMEDICAL, INC. (1)
6,103,734 Drug combination as a medicament to suppress the dependence of individuals to opiates 7 1996
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 50 1988
 
DUPONT PHARMACEUTICALS COMPANY (1)
4,237,140 Analgesic mixture of nalbuphine and acetaminophen 36 1979
 
EASTERN TECHNOLOGY SEED INVESTMENT FUND LIMITED PARTNERSHIP (1)
5,451,408 Pain management with liposome-encapsulated analgesic drugs 51 1994
 
ELAN PHARMA INTERNATIONAL LIMITED (1)
2006/0104,909 Abuse-resistant pharmaceutical compositions 13 2003
 
ELITE LABORATORIES INC. (1)
2004/0202,717 Abuse-resistant oral dosage forms and method of use thereof 15 2003
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 38 1992
 
G. D. SEARLE & CO. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 94 1995
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 29 1991
 
GRUENENTHAL GMBH (1)
2005/0191,244 Abuse-resistant pharmaceutical dosage form 19 2005
 
HARROGATE HOLDINGS (1)
2007/0185,145 Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same 3 2006
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 39 1992
 
INVISTA NORTH AMERICA S.A.R.L. (1)
5,529,813 Process for microstructuring surfaces of oriented polymeric substratesusing laser radiation 12 1995
 
JAGOTEC AB (1)
6,149,940 Tablet with controlled release of alfuzosine chlorhydrate 21 1999
 
MALLINCKRODT LLC (1)
5,529,787 Hydromorphone therapy 16 1994
 
MCGINNIS; CAROLYN (1)
4,608,376 Opiate agonists and antagonists 32 1982
 
MCNEIL AB (1)
5,362,496 Method and therapeutic system for smoking cessation 48 1993
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 38 1997
 
MUTUAL PHARMACEUTICALS, INC. (1)
2003/0124,061 Pharmaceutical safety dosage forms 22 2003
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 37 1991
 
NEW MEXICO TECH RESEARCH FOUNDATION, A NON-PROFIT CORP. OF MEXICO (1)
4,597,961 Transcutaneous application of nicotine 113 1985
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 44 1993
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 39 1992
 
PARNELL PHARMACEUTICALS, INC. (1)
5,219,858 Method and compositions for effecting withdrawal from drug dependency 11 1991
 
PAUL ROYALTY FUND, L.P. (1)
5,780,057 Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids 62 1997
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 29 1995
 
PHARMORX, INC. (1)
2007/0020,339 COMPOSITIONS AND METHODS FOR CONTROLLING ABUSE OF MEDICATIONS 6 2006
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 73 1987
 
RELMADA THERAPEUTICS, INC. (1)
2008/0280,975 Methods of preventing the serotonin syndrome and compositions for use thereof 4 2008
 
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (1)
4,783,456 Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking 11 1987
 
RUBICON RESEARCH PRIVATE LIMITED (1)
2007/0196,396 Controlled release pharmaceutical compositions with improved bioavailability 12 2005
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 70 1986
 
SCHERING AKTIENGESELLSCHAFT (1)
5,385,903 Pharmaceutical agent for treatment of withdrawal symptoms 8 1992
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 26 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,803,208 Opiate agonists and antagonists 36 1985
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 58 1986
 
THE MCLEAN HOSPITAL CORPORATION (1)
5,075,341 Treatment for cocaine abuse 87 1989
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
4,846,199 Smoking of regenerated tobacco smoke 38 1986
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (1)
5,834,477 Opiate analgesic formulation with improved safety 24 1994
 
UNITED BIOMEDICAL, INC. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 31 1995
 
WARNER-LAMBERT COMPANY (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 97 1991
 
WOCKHARDT EUROPE LIMITED (1)
6,635,277 Composition for pulsatile delivery of diltiazem and process of manufacture 4 2001
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 37 1993
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (19)
4,325,465 Auxiliary brake for tractor-trailer rig 26 1980
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 108 1981
4,443,428 Extended action controlled release compositions 53 1982
4,935,429 Method of treating psychostimulant addiction 33 1988
5,376,662 Method of attenuating nerve injury induced pain 34 1993
5,475,995 Truck spare tire locking rod 24 1994
5,919,473 Methods and devices for delivering opioid analgesics to wounds via a subdermal implant 54 1997
2003/0049,317 Method and composition for reducing the danger and preventing the abuse of controlled release pharmaceutical formulations 8 2001
2003/0026,838 Tamper-proof narcotic delivery system 15 2002
2004/0024,004 Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists 6 2002
2004/0024,006 Opioid pharmaceutical compositions 12 2003
2005/0192,309 Method of preventing abuse of opioid dosage forms 3 2003
2004/0092,542 Tamper-resistant oral opioid agonist formulations 11 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 22 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 10 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 8 2003
2004/0176,402 Controlled-release compositions containing opioid agonist and antagonist 6 2003
2009/0028,942 Sustained release compositions of alfuzosin 3 2007
2008/0166,405 Abuse-resistant oral dosage forms and method of use thereof 3 2008

Patent Citation Ranking

Forward Cites

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 23, 2013
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 23, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 23, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00